An Underestimated Sexually Transmitted Infection: Amoebiasis Anne Claire Billet, Arnaud Salmon Rousseau, Lionel Piroth, Capucine Martins

Total Page:16

File Type:pdf, Size:1020Kb

An Underestimated Sexually Transmitted Infection: Amoebiasis Anne Claire Billet, Arnaud Salmon Rousseau, Lionel Piroth, Capucine Martins Reminder of important clinical lesson BMJ Case Rep: first published as 10.1136/bcr-2018-228942 on 10 May 2019. Downloaded from CASE REPORT An underestimated sexually transmitted infection: amoebiasis Anne Claire Billet, Arnaud Salmon Rousseau, Lionel Piroth, Capucine Martins Infectious diseases, Centre SUMMARY 120/60 mm Hg and his pulse was 110 bpm and Hospitalier Universitaire Dijon- Entamoeba histolytica is a cosmopolitan pathogenic regular. He reported losing 5 kg over the past 6 Bourgogne, Dijon, France parasite. It is spread via the feco-oral route and, to a months. His right upper abdominal quadrant was lesser extent, via sexual intercourse. We report a case of hypersensitive, but there was no clinical hepato- Correspondence to hepatic and intestinal amoebiasis in a 67-year-old man megaly or jaundice. No other abnormality was Dr Capucine Martins, capucine3martins@ gmail. com who had never travelled to an endemic area. Abdominal detected. His blood results were as follows: haemo- CT investigations detected two liver abscesses and globin 117 g/L, white blood cells 20×109/L (mainly Accepted 1 May 2019 chronic colitis. Positive amoebic serology and a positive neutrophils), C reactive protein 298 mg/L, total PCR test for E. histolytica in the hepatic liquid and faeces bilirubin 10 µmol/L, serum creatinine 90 mmol/L, confirmed the diagnosis. Curative metronidazole and alanine transaminase (ALT) 38 IU/L, aspartate tiliquinol-tilbroquinol were administered successfully. The transaminase (AST) 23 IU/L and serum albumin patient had been contaminated through heterosexual 19 g/L. He tested negative for HIV, and there was no intercourse with his healthy French female partner who hypogammaglobulinaemia. Abdominal and pelvic was a carrier of the parasite. Though unusual, amoebiasis CT showed two hepatic abscesses in the VI and VII as a result of sexual transmission should be considered segments (58 and 67 mm in diameter, respectively) in non-endemic areas in people who have never travelled (figure 1) and signs of chronic colitis and proctitis abroad, particularly in the presence of clinical symptoms (figures 2 and 3). such as liver abscesses or chronic diarrhoea. INVESTIGATIONS A reddish fluid was aspirated from the hepatic abscesses with the use of ultrasonography (US) BACKGROUND guidance. Blood cultures were sterile. The bacterial Entamoeba histolytica is a protozoan that causes stool culture was negative. The faeces were nega- non-febrile intestinal infection or febrile hepatic tive for Clostridium difficile and Cryptosporidium. http://casereports.bmj.com/ infection, and it is the third most deadly parasitic In the fluid taken from the liver abscess, bacterial infection. Amoebiasis is highly prevalent in low-in- and mycobacterial cultures were negative, but come and middle-income countries and is mainly 1 PCR for E. histolytica was positive. E. histolytica transmitted via the feco-oral route. In high-income was also positive in the faeces. Amoebic serology countries, amoebiasis usually occurs in migrants and was positive with a titre superior to 1/2560 (cut- travellers returning from endemic areas. To a lesser off >1/320), confirming a diagnosis of autochtho- extent, it can be also transmitted sexually, in partic- nous intestinal and hepatic amoebiasis. ular with men who have sex with men.2 Genuine European autochthonous cases are scarce.3–6 We DIFFERENTIAL DIAGNOSIS present here a rare case of a French heterosexually In the case of our patient, three diagnoses were contracted autochthonous amoebiasis. possible (in order of probability): on October 1, 2021 by guest. Protected copyright. 1. A bacterial abscess from a digestive tract infection. CASE PRESENTATION 2. A bacterial abscess secondary to infectious In July 2018, a 67-year-old French man was endocarditis. admitted to hospital for liver pain associated with 3. A parasitic abscess. fever. He was on irbesartan 300 mg per day for chronic hypertension. He was retired from the TREATMENT public service and had a female partner. He had After percutaneous drainage, the patient started © BMJ Publishing Group never travelled outside Europe. on intravenous ceftriaxone 2 g per day and metro- Limited 2019. Re-use Six months previously, he had developed non-fe- nidazole 500 mg three times per day. Ceftriaxone permitted under CC BY-NC. No brile bloody diarrhoea (5–15 stools per day). He commercial re-use. See rights was stopped after 3 days once the amoebic serology and permissions. Published consulted his general practitioner only 3 months was known to be positive. Overall, the patient was by BMJ. after the start of symptoms. The bacterial stool treated with metronidazole for 10 days followed by culture was negative at this time. Ciprofloxacin tiliquinol-tilbroquinol two tablets two times per day To cite: Billet AC, 500 mg two times per day for 7 days was not Salmon Rousseau A, for 10 days. Piroth L, et al. BMJ Case effective. Three months later, he presented to the Rep 2019;12:e228942. emergency room for right upper quadrant pain, OUTCOME AND FOLLOW-UP doi:10.1136/bcr-2018- associated with fever for the past 48 hours. He had Within 48 hours, fever, bloody diarrhoea and 228942 a low-grade fever (38.5°C), blood pressure was hepatic pain disappeared, and most of his laboratory Billet AC, et al. BMJ Case Rep 2019;12:e228942. doi:10.1136/bcr-2018-228942 1 Reminder of important clinical lesson BMJ Case Rep: first published as 10.1136/bcr-2018-228942 on 10 May 2019. Downloaded from Figure 1 Abdominal CT showing the two cystic abscess cavities. parameters normalised. At follow-up 2 months later, no recur- rence was observed and the stool sample was negative. W AY OF TRANSMISSION The patient had never travelled outside of Europe, but his French Figure 3 Abdominal CT showing simultaneous intestinal and hepatic female partner had travelled in endemic areas including South amoebiasis. America, India, Burma, Vietnam and Laos. She had also had a prior heterosexual relationship with a man who was diagnosed with intestinal amoebiasis. She had never presented symptoms. transmitted cases have been reported, but three cases of hepatic abscesses were reported in a group of Canadian tourists who had Her serology was positive with a titre superior to 1/2560, but 8 abdominal US did not show liver abscess. She was started on intergroup sexual relationships. More recently in France, a case of amoebiasis was reported in a male with no risk factor apart metronidazole 500 mg three times daily for 10 days followed 5 by tiliquinol-tilbroquinol two tablets twice daily for 10 days. At from a sexual relationship with a South African woman. follow-up 2 months later, E. histolytica serology was negative. Our patient presented simultaneous intestinal and liver amoe- biasis. Classically, intestinal mucosa invasion leads to an intestinal http://casereports.bmj.com/ infection, which then develops into ulcerations and microab- DISCUSSION scesses, resulting in non-febrile (bloody) diarrhoeas. Then, the Though European cases are quite rare, E. histolytica proto- liver may be infected by invasion of the portal venous system. zoan is cosmopolitan and autochthonous cases may occur in Hepatic tissue necrosis creates hepatitis abscesses resulting in metropolitan France.3–5 A diagnosis of E. histolytica should not pain and fever.1 To our knowledge, there are very few cases of be ruled out only because the patient has not visited travel in simultaneous intestinal and hepatic clinical forms in the liter- endemic areas. Though it is transmitted via the feco-oral route, ature.9 10 Hepatic abscesses are more prevalent in males and it may also be to a lesser extent sexually transmitted from are associated with gastrointestinal symptoms in 10%–35% of healthy carriers. Additional risk factors for amoebiasis infec- patients.1 tion have been identified, such as men having sexual relation- Intestinal amoebiasis is usually confirmed with a parasitic on October 1, 2021 by guest. Protected copyright. ship with men,2 HIV coinfection7 or oro-anal sexual practices,8 stool culture, a PCR-based test or presence of E. histolytica on but our patient confirmed having an exclusively heterosexual colonic mucosal biopsy specimens. Hepatic amoebiasis can be relationship with his female partner.9 Very few heterosexually confirmed with serology (gold standard), but its positivity may be sometimes delayed. Most of time aspiration of the abscess is required to rule out a pyogenic abscess. Occasionally, the abscess may require drainage in patients who fail to respond to drug therapy with a high risk of abscess rupture (cavity with a diam- eter of more than 5 cm) or for pain relief.1 Treatment for intestinal or hepatic amoebiasis consists of a sequence of two antiparasitic therapies. First, a nitroimidazole drug is prescribed, specifically metronidazole (500 mg three times per day for 10 days), followed by a luminal infection cure such as tiliquinol-tilbroquinol (two tablets two times per day for 10 days) or diloxanide furoate. Treatment of the luminal infec- tion is needed to avoid a relapse. Clinical follow-up is associated with a stool culture 3–4 weeks after the end of treatment.2 As amoebiasis can be transmitted via sexual route, it is essential to identify and treat sexual partners to avoid recontamination. This Figure 2 Abdominal CT showing chronic colitis. is important in developed countries like France where, though 2 Billet AC, et al. BMJ Case Rep 2019;12:e228942. doi:10.1136/bcr-2018-228942 Reminder of important clinical lesson BMJ Case Rep: first published as 10.1136/bcr-2018-228942 on 10 May 2019. Downloaded from recent epidemiological data are lacking, it has been suggested Funding The authors have not declared a specific grant for this research from any that 11% of sewer workers and 2% of the general popula- funding agency in the public, commercial or not-for-profit sectors.
Recommended publications
  • An Unusual Case of Amoebic Liver Abscess Presenting with Hepatic Encephalopathy: a Case Report
    Case Report An Unusual Case of Amoebic Liver Abscess Presenting with Hepatic Encephalopathy: A Case Report Anil Kumar SARDA, Rakesh MITTAL Submitted: 16 Sep 2010 Department of Surgery, Maulana Azad Medical College and Lok Nayak Accepted: 3 Jan 2011 Hospital, New Delhi 110 002, India Abstract Amoebic liver abscess (ALA) with jaundice and encephalopathy is a rare occurrence and has been recognised and studied more frequently in recent years. We present a case of massive ALA presenting with jaundice, hepatic encephalopathy, and septicaemia that was treated successfully with percutaneous drainage of the abscess, right-sided chest tube insertion, and anti-amoebic therapy. Keywords: amoebiasis, hepatic encephalopathy, hepatology, jaundice, liver abscess Introduction On chest examination, there was bilateral equal air entry. Upon investigation, haemoglobin was Amoebic liver abscess (ALA) is the most 11 g/dL, with a total leukocyte count of frequent extra-intestinal manifestation of 13 000 cells/mm3 (normal range is 4000– Entamoeba histolytica infection. It has been 11 000 cells/mm3). Liver function tests revealed reported that jaundice is uncommon and mild total serum bilirubin of 20 mg/dL, with direct in liver abscess, and some even consider the bilirubin of 15 mg/dL, serum glutamic-oxaloacetic presence of jaundice as a feature against the transaminase (SGOT) of 324 IU/L (normal level diagnosis of hepatic amoebiasis (1). The cause of is less than 40 IU/L), serum glutamic–pyruvic jaundice in a case of ALA has been hypothesised transaminase (SGPT) of 340 IU/L (normal level to result from either hepatocellular dysfunction or is less than 40 IU/L), and alkaline phosphatase intrahepatic biliary obstruction (2).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Amebiasis Annual Report 2017
    Amebiasis Annual Report 2017 Amebiasis Amebiasis is no longer a reportable disease in Louisiana. Outbreaks, however, should still be reported. Amebiasis (amoebiasis) is a parasitic infection caused by Entamoeba histolytica or Entamoeba dispar. The parasite is transmitted by the fecal-oral route, either through direct contact with feces or through the consumption of contaminated food or water. Between 80% and 90% of infected individuals develop no symptoms. For symptomatic cases, the incubation period between infection and illness can range from days to weeks. The symptoms are typically gastrointestinal issues, such as diarrhea or stomach pains. It is also possible for the parasite to spread to the liver and cause abscesses. Entamoeba histolytica can be found world-wide, but is more prevalent in tropical regions with poor sanitary conditions. In some areas with extremely adverse conditions, the prevalence can be as high as 50% in the population. There are no recent data on prevalence of amebiasis in the U.S. however, prevalence is estimated to be between 1% and 4% of the population. High risk groups are refugees, recent immigrants, travelers (particularly those who have spent long periods of time in an endemic area), institutionalized people (particularly developmentally or mentally-impaired people), and men who have sex with men. The number of cases reported within Louisiana is usually low. There are typically less than ten cases per year with a few exceptions (Figure 1). Figure 1: Amebiasis cases - Louisiana, 1970-2017 40 35 30 25 20 15 Number of Cases Number 10 5 0 70 72 74 76 78 80 82 84 86 88 90 92 94 96 98 00 02 04 06 08 10 12 14 16 Year Louisiana Office of Public Health – Infectious Disease Epidemiology Section Page 1 of 4 Amebiasis Annual Report 2017 Hospitalization Hospitalization surveillance is based on Louisiana Hospital Inpatient Discharge Data (LaHIDD).
    [Show full text]
  • Surveillance Study of Acute Gastroenteritis Etiologies in Hospitalized Children in South Lebanon (SAGE Study)
    pISSN: 2234-8646 eISSN: 2234-8840 https://doi.org/10.5223/pghn.2018.21.3.176 Pediatr Gastroenterol Hepatol Nutr 2018 July 21(3):176-183 Original Article PGHN Surveillance Study of Acute Gastroenteritis Etiologies in Hospitalized Children in South Lebanon (SAGE study) Ghassan Ghssein, Ali Salami, Lamis Salloum, Pia Chedid*, Wissam H Joumaa, and Hadi Fakih† Rammal Hassan Rammal Research Laboratory, Physio-toxicity (PhyTox) Research Group, Lebanese University, Faculty of Sciences (V), Nabatieh, *Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Balamand, †Department of Pediatrics, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon Purpose: Acute gastroenteritis (AGE) is a major cause of morbidity and remains a major cause of hospitalization. Following the Syrian refugee crisis and insufficient clean water in the region, this study reviews the etiological and epidemiological data in Lebanon. Methods: We prospectively analyzed demographic, clinical and routine laboratory data of 198 children from the age of 1 month to 10 years old who were admitted with the diagnosis of AGE to a private tertiary care hospital located in the district of Nabatieh in south Lebanon. Results: Males had a higher incidence of AGE (57.1%). Pathogens were detected in 57.6% (n=114) of admitted pa- tients, among them single pathogens were found in 51.0% (n=101) of cases that consisted of: Entamoeba histolytica 26.3% (n=52), rotavirus 18.7% (n=37), adenovirus 6.1% (n=12) and mixed co-pathogens found in 6.6% (n=13). Breast-fed children were significantly less prone to rotavirus (p=0.041). Moreover, children who had received the rota- virus vaccine were significantly less prone to rotavirus (p=0.032).
    [Show full text]
  • Amoebic Colitis Presenting As Subacute Intestinal Obstruction with Perforation
    International Journal of TROPICAL DISEASE & Health 41(16): 58-62, 2020; Article no.IJTDH.61831 ISSN: 2278–1005, NLM ID: 101632866 Amoebic Colitis Presenting as Subacute Intestinal Obstruction with Perforation Renuka Verma1, Archana Budhwar1*, Priyanka Rawat1, Niti Dalal1, Anjali Bishlay1 and Sunita Singh1 1Pt. B. D. Sharma Post Graduate Institute of Medical Sciences, Rohtak-124001, Haryana, India. Authors’ contributions This work was carried out in collaboration among all authors. Authors RV and SS designed the study, reviewed the manuscript and edited it. Author Archana Budhwar wrote the protocol and wrote the first draft of the manuscript. Author PR managed the literature searches. Authors ND and Anjali Bishlay managed the analyses of the study. All authors read and approved the final manuscript. Article Information DOI: 10.9734/IJTDH/2020/v41i1630367 Editor(s): (1) Dr. Giuseppe Murdaca, University of Genoa, Italy. Reviewers: (1) Ammar M. Al-Aalim, Mosul University, Iraq. (2) Tarunbir Singh, Guru Angad Dev Veterinary & Animal Sciences University, Ludhiana. Complete Peer review History: http://www.sdiarticle4.com/review-history/61831 Received 10 August 2020 Case Study Accepted 16 October 2020 Published 12 November 2020 ABSTRACT Infestation with Entamoeba histolytica is worldwide, especially in developing areas. Presented case study included amoebic colitis in a 45 years old man complaining of abdominal distension and non- passage of stools since three days. Abdominal region was diffusely distended and tender in right iliac fossa. Plain abdominal radiography revealed prominent gut loops and minimal intergut free fluid. At laparotomy, malrotation of gut was present. Histopathological examination of intestinal samples confirmed final diagnosis of amoebic colitis post-operatively.
    [Show full text]
  • Improved Genomic Assembly and Genomic Analyses of Entamoeba Histolytica
    Improved genomic assembly and genomic analyses of Entamoeba histolytica Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy by Amber Leckenby September 2018 Acknowledgements There are many people without whom this thesis would not have been possible. The list is long and I am truly grateful to each and every one. Firstly I have to thank my supervisors Gareth, Christiane, Neil and Steve for the continuous support throughout my PhD. Particularly, I am grateful to Gareth and Christiane, for their patience, motivation and immense knowledge that helped me through the entirety of the proJect from the initial research to the writing of this thesis. I cannot have imagined having better mentors and role models. I also have to thank the staff at the CGR for their role in the sequencing aspects of this thesis. My further thanks extend to the CGR bioinformatics team, most notably Richard, Matthew, Sam and Luca, for not only tolerating the number of bioinformatics questions I have asked them, but also providing great friendship and warmth in the office. I must also give a special mention to Graham Clark at the London School of Hygiene and Tropical Medicine for sending cultures of Entamoeba and providing general advice, especially around the tRNA arrays. I would also like to thank David Starns, for his efforts troubleshooting the Companion pipeline and to Laura Gardiner for providing advice around all things methylation. My gratitude goes to the members of the many offices I have moved around during my PhD, many of which have become close friends who have got me through many bioinformatics conundrums, lab meltdowns and (some equally challenging) gym sessions.
    [Show full text]
  • UTILISATION DES ANTI-INFECTIEUX ET GROSSESSE Ce Tableau N’A Qu’Une Valeur Indicative Et Ne Constitue Qu’Une Aide À La Prescription
    UTILISATION DES ANTI-INFECTIEUX ET GROSSESSE Ce tableau n’a qu’une valeur indicative et ne constitue qu’une aide à la prescription. L’évaluation devra se faire au cas par cas. Pour plus d’information, contacter le Centre Régional de Pharmacovigilance au 04 73 75 48 31. CONDUITE A TENIR D’UTILISATION ANTI-INFECTIEUX 1er TRIMESTRE 2ème TRIMESTRE et 3ème TRIMESTRE · Possible : 1ère intention : amoxicilline, ampicilline, Pénicilline V, G, amoxicilline-acide clavulanique PENICILLINES · Possible : 2ème intention : cloxacilline, oxacilline, ampicilline-sulbactam, pipéracilline, pipéracilline-tazobactam, ticarcilline, ticarcilline-acide clavulanique · Possible : 1ère intention : C1G (céfadroxil, céfalexine, cefaclor) ; C2G (céfuroxime) ; C3G (ceftriaxone) · Possible : 2ème intention : C1G (céfalotine, céfatrizine, céfazoline, céfradine), C2G (céfamandole, cefoxitine) ; C3G (céfotaxime, ceftazidime, céfépime, CEPHALOSPORINES cefpirome, cefixime, cefotiam, cefpodoxime) · A éviter par prudence : ceftaroline AUTRES BETALACTA- · Possible : 2ème intention : imipénem –cilastatine MINES · A éviter par prudence : aztréonam, doripénème, ertapénème, méropénem · Possible 1ère intention : azithromycine, érythromycine, spiramycine · Possible 2ème intention : josamycine, clarithromycine, roxithromycine MACROLIDES · A éviter par prudence : midécamycine · Déconseillé : télithromycine STREPTOGRAMINES · Possible 2ème intention : pristinamycine · Possible 1ère intention : clindamycine · Possible 1ère intention : clindamycine LINCOSAMIDES · A éviter : lincomycine
    [Show full text]
  • Granulomatous Meningoencephalitis Balamuthia Mandrillaris in Peru: Infection of the Skin and Central Nervous System
    SMGr up Granulomatous Meningoencephalitis Balamuthia mandrillaris in Peru: Infection of the Skin and Central Nervous System A. Martín Cabello-Vílchez MSc, PhD* Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical “Alexander von Humboldt” *Corresponding author: Instituto de Medicina Tropical “Alexander von Humboldt”, Av. Honorio Delgado Nº430, San A. Martín Cabello-Vílchez, Universidad Peruana Cayetano Heredia, MartínPublished de Porras, Date: Lima-Perú, Tel: +511 989767619, Email: [email protected] February 16, 2017 ABSTRACT Balamuthia mandrillaris is an emerging cause of sub acute granulomatous amebic encephalitis (GAE) or Balamuthia mandrillaris amoebic infection (BMAI). It is an emerging pathogen causing skin lesions as well as CNS involvement with a fatal outcome if untreated. The infection has been described more commonly in inmunocompetent individuals, mostly males, many children. All continents have reported the disease, although a majority of cases are seen in North and South America, especially Peru. Balamuthia mandrillaris is a free living amoeba that can be isolated from soil. In published reported cases from North America, most patients will debut with neurological symptoms, where as in countries like Peru, a skin lesion will precede neurological symptoms. The classical cutaneous lesionis a plaque, mostly located on face, knee or other body parts. Diagnosis requires a specialized laboratory and clinical experience. This Amoebic encephalitis may be erroneously interpreted as a cerebral neoplasm, causing delay in the management of the infection. Thediagnosis of this infection has proven to be difficult and is usually made post-mortem but in Peru many cases were pre-morten. Despite case fatality rates as high as > 98%, some experimental therapies have shown protozoal therapy with macrolides and phenothiazines.
    [Show full text]
  • 3-Treatment of Dysentery and Amoebiasis .Pdf
    Treatment of dysentery and amoebiasis Objectives: 1. To understand different causes of dysentery. 2. To describe different classes of drugs used in treatment of both bacillary dysentery and amebic dysentery. 3. To be able to describe actions, side effects of drugs for treating bacillary dysentery. 4. To understand the pharmacokinetics, actions, clinical applications and side effects of antiamebic drugs. 5. to be able to differentiate between types of antiamebic drugs; luminal amebicides, and tissue amebicide. Editing File Color index: Important Note Extra Mind Maps Mnemonics Metronidazole اﻟﻤﯿﺘﻮ ﯾﻤﺸﻲ ﻻﻣﺎﻛﻦ ﺑﻌﯿﺪه ﻓﯿﺼﯿﺮ ﻧﺴﺘﺨﺪم ھﺬا اﻟﺪرق ﻓﻲ( Metro → systemic amoebicides( trophozoites - ﻧﺪى ﻗﺮﯾﯿﯿﺐ ﻣﻦ DNA ﻓﮭﻮ ﯾﺴﻮي اﻧﮭﺒﺖ ﻟﺪي ان اي رﯾﺒﻠﯿﻜﯿﺸﻦ → Nida - ﺟﺎﯾﮫ اﺣﺎول اﺻﯿﺮ طﺒﯿﺒﺔ اﺳﻨﺎن ﺑﺲ ﻗﺎﻟﻮا ﻟﻲ ﺑﻮو ﯾﺎ ﻛﺬاﺑﮫ !Clinical uses : Gia tri pu pseudo - .giardiasis → (ﺟﺎﯾﮫ) Gia - .trichomoniasis → (اﺣﺎول) Tri - طﺒﯿﺒﺔ أﺳﻨﺎن → ﯾﺴﺘﺨﺪم ﻓﻲ اﻟﺪﯾﻨﺘﺎل ﺑﺮاﻛﺘﺲ- .peptic ulcer → (ﺑﻮ) Pu - pseudomembranous colitis → (ﻛﺬاﺑﮫ)Pseudo - ﻧﺪى طﺒﯿﺒﺔ اﺳﻨﺎن طﯿﺐ ؟ : ADRs- ﺣﻄﺖ اﻟﺴﯿﻜﺸﻦ وﺻﺎر اﻟﻔﻢ ﺟﺎااف (dry mouth) ﺛﻢ ﺣﻄﺖ اﻟﺒﻨﺞ وﺻﺎر طﻌﻤﮫ ﻣﻮ ﺣﻠﻮ (metallic taste ) ﻋﺎد ﻧﺪى ﻛﺜﺮت ﺑﻨﺞ وﻛﺎن ﯾﺤﺒﮫ اﻟﻔﻨﻘﻞ ﻟﯿﻦ ﺳﻮى ﻟﻲoral thrush وﺑﻌﺪ ﻣﻦ ﻛﺜﺮة اﻟﺒﻨﺞ داﺧﺖ اﻟﺒﯿﺸﻨﺖ وﺻﺎر ﻋﻨﺪھﺎ neurotoxicological effect وﻟﻼﺳﻒ اﻟﺒﯿﺸﺖ ﺑﻠﻌﺖ ﻧﺺ اﻟﺒﻨﺞ وطﻠﻊ ﻣﻊ اﻟﯿﻮرن (dysuria ) وﻻﻧﮭﺎ اﺧﺬت ﻛﺤﻮل ﻗﺒﻞ ﺗﺮوح ﻟﻠﺪﻛﺘﻮره ﻧﺪى ﺻﺎر ﻓﯿﮫ ﺗﻌﺎرض ﻣﻊ اﻟﺒﻨﺞ اﻟﻠﻲ ﺑﻠﻌﺘﮫ (disulfiram like effect) . Emetine وﺣﺪه ﻣﻮﺻﯿﮫ اﺧﺘﮭﺎ ﺗﺠﯿﺐ ﻟﮭﺎ ﺑﺮوﺗﯿﻦ ﺑﺎر ، طﻮﻟﺖ اﺧﺘﮭﺎ ودﻗﺖ ﻋﻠﯿﮭﺎ ﻗﺎﻟﺖ اﻣﺘﺎ ﺗﺠﯿﻦ طﻮﻟﺘﻲ ؟ (emetine) ﻗﺎﻟﺖ اﺧﺘﮭﺎ ﻣﺎرااح اﺟﻲ وﻣﺎﻓﯿﮫ ﺑﺮوﺗﯿﻦ ﺑﺎر ، ﻓﺎﯾﺸﯿﺴﻮي
    [Show full text]
  • Entamoeba Histolytica - Wikipedia, the Free Encyclopedia • Ten Things You May Not Know About Wikipedia • 23,333 Have Donated
    Entamoeba histolytica - Wikipedia, the free encyclopedia • Ten things you may not know about Wikipedia • 23,333 have donated. You can help Wikipedia change the world! » Donate now! "So that others may enjoy the gift of knowledge" — Anon. [Hide this message] Entamoeba histolytica From Wikipedia, the free encyclopedia Jump to: navigation, search Entamoeba histolytica Entamoeba histolytica cyst Scientific classification Domain: Eukaryota Phylum: Amoebozoa Class: Archamoebae Genus: Entamoeba Species: E. histolytica For the infection and disease caused by this parasite, refer to Amoebiasis. Entamoeba histolytica is an anaerobic parasitic protozoan, part of the genus Entamoeba. It infects predominantly humans and other primates. It is estimated that about 50 million people are infected with the parasite worldwide. Diverse mammals such as dogs and cats can become infected but are not http://en.wikipedia.org/wiki/Entamoeba_histolytica (1 of 5)13/11/2550 13:08:05 Entamoeba histolytica - Wikipedia, the free encyclopedia thought to contribute significantly to transmission. The active (trophozoite) stage exists only in the host and in fresh loose feces; cysts survive outside the host in water, soils and on foods, especially under moist conditions on the latter. When cysts are swallowed they cause infections by excysting (releasing the trophozoite stage) in the digestive tract. E. histolytica, as its name suggests (histo–lytic = tissue destroying), causes disease; infection can lead to amoebic dysentery or amoebic liver abscess. Symptoms can include fulminating dysentery, diarrhea, weight loss, fatigue, abdominal pain, and amebomas. The amoeba can actually 'bore' into the intestinal wall, causing lesions and intestinal symptoms, and it may reach the blood stream. From there, it can reach different vital organs of the human body, usually the liver, but sometimes the lungs, brain, spleen, etc.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]